Research ArticleOriginal Article
Open Access

Biomarker for cardiorenal syndrome risk in patients with liver cirrhosis and type 2 diabetes in Saudi Arabia

Walaa Mohammedsaeed and Zain J Alghamdi
Saudi Medical Journal July 2024, 45 (7) 675-684; DOI: https://doi.org/10.15537/smj.2024.45.7.20240156

References

  1. 1.↵
    1. Nakahara T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD),
    2. Hyogo H,
    3. Yoneda M,
    4. Sumida Y,
    5. Eguchi Y, et al.
    Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol 2013: 49; 1477–1484.
    OpenUrl
  2. 2.↵
    1. Hamaguchi M,
    2. Kojima T,
    3. Takeda N,
    4. Nakagawa T,
    5. Taniguchi H,
    6. Fujii K, et al.
    The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005: 143; 722–728.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Lee DS,
    2. Gona P,
    3. Vasan RS,
    4. Larson MG,
    5. Benjamin EJ,
    6. Wang TJ, et al.
    , Relation of disease pathogenesis and risk factors to HF with preserved or reduced ejection fraction: Insights from the framingham heart study of the national heart, lung, and blood institute. Circulation. 2009:119;3070–3077.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Kenchaiah S,
    2. Evans JC,
    3. Levy D,
    4. Wilson PW,
    5. Benjamin EJ,
    6. Larson MG, et al.
    Obesity and the risk of HF. N Engl J Med 2002: 347; 305–313.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Nichols GA,
    2. Gullion CM,
    3. Koro CE,
    4. Ephross SA,
    5. Brown JB
    . The incidence of congestive HF in type 2 diabetes: An update. Diabetes Care 2004: 27; 1879–1884.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Imajo K,
    2. Hyogo H,
    3. Yoneda M,
    4. Honda Y,
    5. Kessoku T,
    6. Tomeno W,
    7. Ogawa Y, et al.
    LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty Liver: A multicenter cross-sectional study. PLoS One 2014: 9; e115403.
    OpenUrl
  7. 7.↵
    1. Verbrugge FH,
    2. Dupont M,
    3. Steels P,
    4. Grieten L,
    5. Malbrain M,
    6. Tang WW, et al.
    Abdominal contributions to cardiorenal dysfunction in congestive HF. J Am Coll Cardiol 2013: 62; 485–495.
    OpenUrlFREE Full Text
  8. 8.↵
    1. Kim D,
    2. Kim WR,
    3. Kim HJ,
    4. Therneau TM
    . Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2012: 57; 1357–1365.
    OpenUrl
  9. 9.↵
    1. Ruospo M,
    2. Saglimbene VM,
    3. Palmer SC
    . Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev 2017: 6; CD010137.
    OpenUrl
  10. 10.↵
    1. Jung HH,
    2. Lee S
    . Optimal fasting glucose levels with regard to cardiovascular and mortality outcomes in people treated with or without antidiabetic medication. Diabetes Obes Metab 2020; 22: 243-253.
    OpenUrl
  11. 11.↵
    1. Ronco C,
    2. Di Lullo L
    . Cardiorenal syndrome in Western countries: Epidemiology, diagnosis and management approaches. Kidney Dis (Basel) 2017; 2: 151-163.
    OpenUrl
  12. 12.↵
    1. Di Lullo L,
    2. Bellasi A,
    3. Barbera V,
    4. Russo D,
    5. Russo L,
    6. Di Iorio B, et al.
    Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate. Indian Heart J 2017; 69: 255-265.
    OpenUrlCrossRef
  13. 13.
    1. Bongartz LG,
    2. Cramer MJ,
    3. Doevendans PA,
    4. Joles JA,
    5. Braam B
    . The severe cardiorenal syndrome: “Guyton revisited” Eur Heart J 2005; 26: 11-17.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Thind GS,
    2. Loehrke M,
    3. Wilt JL
    . Acute cardiorenal syndrome: Mechanisms and clinical implications. Cleve Clin J Med 2018; 85: 231-239.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Angermayr B,
    2. Cejna M,
    3. Karnel F
    . Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 2003; 52: 879-885.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    MDCalc. Child-Pugh Score for Cirrhosis Mortality. [updated 2021; Accessed 1 January 2022]. Available from: https://www.mdcalc.com/calc/340/child-pugh-score-cirrhosis-mortality
  17. 17.↵
    World Health Organization. International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. [Accessed 13 September 2022]. Available from: https://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf
  18. 18.↵
    Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Levey AS,
    2. Coresh J,
    3. Tighiouart H,
    4. Greene T,
    5. Inker LA
    . Measured and estimated glomerular filtration rate: current status and future directions. Nat Rev Nephrol 2020; 16: 51-64.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Ito S,
    2. Ueno M,
    3. Izumi T,
    4. Arakawa M
    . Induction of transient proteinuria, hematuria, and glucosuria by ethanol consumption in Japanese alcoholics. Nephron 1999; 82: 246-253.
    OpenUrlPubMed
  21. 21.↵
    KDIGO. Summary of recommendation statements. Kidney Int Suppl (2011) 2013; 3: 5-14.
    OpenUrlCrossRef
  22. 22.↵
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Bosomworth NJ
    . Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. Can Fam Physician 2013; 59: 1169-1180.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Whelton PK,
    2. Carey RM,
    3. Aronow WS,
    4. Casey DE Jr.,
    5. Collins KJ,
    6. Himmelfarb CD
    . ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Hypertension 2018; 71: e13–e115.
    OpenUrl
  25. 25.↵
    WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Gallo G,
    2. Lanza O,
    3. Savoia C
    . New insight in cardiorenal syndrome: From biomarkers to therapy. Int J Mol Sci 2023; 24: 5089.
    OpenUrl
  27. 27.↵
    1. Schefold JC,
    2. Filippatos G,
    3. Hasenfuss G,
    4. Anker SD,
    5. von Haehling S
    . HF and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol 2016; 12: 610-623.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Carlström M,
    2. Wilcox CS,
    3. Arendshorst WJ
    . Renal autoregulation in health and disease. Physiol Rev 2015; 9: 405-511.
    OpenUrl
  29. 29.↵
    1. Ljungman S,
    2. Laragh JH,
    3. Cody RJ
    . Role of the kidney in congestive HF. Relationship of cardiac index to kidney function. Drugs 1990; 39: 10-21.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Damman K,
    2. van Deursen VM,
    3. Navis G,
    4. Voors AA,
    5. van Veldhuisen DJ,
    6. Hillege HL
    . Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53: 582-588.
    OpenUrlFREE Full Text
  31. 31.↵
    1. Grassi G,
    2. Fowler B,
    3. Scali B,
    4. Rossi F,
    5. Motto E,
    6. Pieruzzi F, et al.
    Sympathetic activation and heart rate thresholds for cardiovascular risk in chronic kidney disease. J Hypertens 2022; 40: 1530-1536.
    OpenUrl
  32. 32.↵
    1. Sharp TE, 3rd.,
    2. Lefer DJ
    . Renal denervation to treat HF. Annu Rev Physiol 2021; 83: 39-58.
    OpenUrl
  33. 33.↵
    1. Junho CVC,
    2. Trentin-Sonoda M,
    3. Panico K,
    4. Dos Santos RSN,
    5. Abrahão MV,
    6. Vernier ICS, et al.
    Cardiorenal syndrome: long road between kidney and heart. Heart Fail Rev 2022; 27: 2137-2153.
    OpenUrl
  34. 34.↵
    1. Damman K,
    2. Testani JM
    . The kidney in HF: an update. Eur Heart J 2015; 36: 1437-1444.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Ronco C,
    2. McCullough P,
    3. Anker SD,
    4. Anand I,
    5. Aspromonte N,
    6. Bagshaw SM, et al.
    Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2009; 31: 703-711.
    OpenUrlPubMedWeb of Science
  36. 36.↵
    1. Hu W,
    2. He W,
    3. Liu W,
    4. Fang X,
    5. Wu Y,
    6. Yu F, et al.
    Risk Factors and Prognosis of Cardiorenal Syndrome Type 1 in Elderly Chinese Patients: A Retrospective Observational Cohort Study. Kidney Blood Press Res 2016; 41: 672-679.
    OpenUrl
  37. 37.↵
    1. Ronco C,
    2. Cicoira M,
    3. McCullough PA
    . Cardiorenal syndrome type 1: Pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated HF. J Am Coll Cardiol 2012; 60: 1031-1042.
    OpenUrlFREE Full Text
  38. 38.↵
    1. Agrawal V,
    2. Krause KR,
    3. Chengelis DL,
    4. Zalesin KC,
    5. Rocher LL,
    6. McCullough PA
    . Relation between degree of weight loss after bariatric surgery and reduction in albuminuria and C-reactive protein. Surg Obes Relat Dis 2009; 5: 20-26.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Ouwens DM,
    2. Sell H,
    3. Greulich S,
    4. Eckel J
    . The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. J Cell Mol Med 2010;14: 2223-2234.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Otero-Losada M,
    2. Gómez Llambí H,
    3. Ottaviano G,
    4. Cao G,
    5. Müller A,
    6. Azzato F, et al.
    Cardiorenal Involvement in Metabolic Syndrome Induced by Cola Drinking in Rats: Proinflammatory Cytokines and Impaired Antioxidative Protection. Mediators Inflamm 2016;2016:5613056.
    OpenUrl
  41. 41.↵
    1. Lee SE,
    2. Yoo J,
    3. Kim B-S,
    4. Choi HS,
    5. Han K,
    6. Kim K-A
    . The effect of metabolic dysfunction-associated fatty liver disease and diabetic kidney disease on the risk of hospitalization of HF in type 2 diabetes: a retrospective cohort study. Diabetol Metab Syndr 2023; 15: 32.
    OpenUrl
  42. 42.↵
    1. Dhingra R,
    2. Gaziano JM,
    3. Djoussé L
    . Chronic kidney disease and the risk of HF in men. Circ Heart Fail 2011; 4: 138-144.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Lena A,
    2. Anker MS,
    3. Springer J
    . Muscle wasting and sarcopenia in HF—the current state of science. Int J Mol Sci 2020; 21: 6549.
    OpenUrl
  44. 44.↵
    1. Lassus JP,
    2. Nieminen MS,
    3. Peuhkurinen K,
    4. Pulkki K,
    5. Siirilä-Waris K,
    6. Sund R, et al.
    Markers of renal function and acute kidney injury in acute HF: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J 2010; 31: 2791-2798.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Kevin D,
    2. Dirk JVV,
    3. Gerjan N,
    4. Vishal SV,
    5. Tom DJS,
    6. Westenbrink BD, et al.
    Tubular damage in chronic systolic HF is associated with reduced survival independent of glomerular filtration rate. Heart 2010; 96: 1297.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Schechter M,
    2. Melzer Cohen C,
    3. Yanuv I,
    4. Rozenberg A,
    5. Chodick G,
    6. Bodegård J, et al.
    Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults. Cardiovasc Diabetol 2022; 21: 104.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords